Bürki, Susanne; Brand, Béatrice; Escher, Robert; Wuillemin, Walter A; Nagler, Michael; Nagler, Michael (2018). Accuracy, reproducibility and costs of different laboratory assays for the monitoring of unfractionated heparin in clinical practice: a prospective evaluation study and survey among Swiss institutions. BMJ open, 8(6), e022943. BMJ Publishing Group 10.1136/bmjopen-2018-022943
|
Text
SB_Accuracy, resporducibility and costs of _e022943.full.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (625kB) | Preview |
OBJECTIVES
To investigate the accuracy, reproducibility and costs of different laboratory assays for the monitoring of unfractionated heparin (UFH) in clinical practice and to study test utilisation in Switzerland.
DESIGN
Prospective evaluation study and survey among Swiss hospitals and laboratories.
SETTING
Secondary care hospital in rural Switzerland (evaluation study); all Swiss hospitals and laboratories (survey).
PARTICIPANTS
All consecutive patients, monitored for treatment with UFH during two time periods, were included (May to July 2014 and January to February 2015; n=254).
OUTCOME MEASURES
Results of activated partial thromboplastin time (aPTT), thrombin time (TT), prothrombinase-induced clotting time (PiCT) and anti-Xa activity with respect to UFH concentration RESULTS: Spearman's correlation coefficient (r) with regard to anti-Xa activity was 0.68 (95% CI 0.60 to 0.75) for aPTT, 0.79 (0.69 to 0.86) for TT and 0.94 (0.93 to 0.95) for PiCT. The correlation (r) between anti-Xa activity and heparin concentration as determined by spiking plasma samples was 1.0 (1.0 to 1.0). The coefficient of variation was at most 5% for PiCT and anti-Xa activity (within-run as well as day-to-day variability). The total costs per test in Swiss Francs (SFr) were SFr23.40 for aPTT, SFr33.30 for TT, SFr15.70 for PiCT and SFr24.15 for anti-Xa activity. The various tests were employed in Swiss institutions with the following frequencies: aPTT 53.2%, TT 21.6%, anti-Xa activity 7.2%, PiCT 1.4%; 16.6% of hospitals performed more than one test.
CONCLUSIONS
The accuracy and reproducibility of PiCT and anti-Xa activity for monitoring of UFH was superior, and analytical costs were equivalent to or lower than aPTT and TT.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene) |
UniBE Contributor: |
Bürki, Susanne, Nagler, Michael |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2044-6055 |
Publisher: |
BMJ Publishing Group |
Language: |
English |
Submitter: |
Pierrette Durand Lüthi |
Date Deposited: |
04 Oct 2018 08:30 |
Last Modified: |
05 Dec 2022 15:18 |
Publisher DOI: |
10.1136/bmjopen-2018-022943 |
PubMed ID: |
29886450 |
Uncontrolled Keywords: |
drug monitoring health care costs heparin/therapy partial thromboplastin time thrombin time |
BORIS DOI: |
10.7892/boris.120296 |
URI: |
https://boris.unibe.ch/id/eprint/120296 |